SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Mankind Pharma Ltd

BSE: 543904 NSE: MANKIND ISIN: INE634S01028
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Mankind Pharma Ltd belong to?
Mankind Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Mankind Pharma Ltd a good quality company?
Mankind Pharma Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Mankind Pharma Ltd undervalued or overvalued?
Mankind Pharma Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Mankind Pharma Ltd a good buy now?
Mankind Pharma Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Mankind Pharma Ltd?
Mankind Pharma Ltd revenue growth is 10.1% for FY-2025 , which is below its 5 year CAGR of 14.7% , indicating slower growth.
Q.2 Gross Profit margin of Mankind Pharma Ltd?
Mankind Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 27.5% for FY-2025 , which is above its 5 year median of 26.5% , indicating increasing margins.
Q.3 Operating Profit Margin of Mankind Pharma Ltd?
Mankind Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 26.99% for FY-2025 , which is above its 5 year median of 24.91% indicating increasing margins.
Q.4 Net Profit Margin of Mankind Pharma Ltd?
Mankind Pharma Ltd Net Profit Margin is 19.84% for FY-2025 , is above with its 5 year median of 19.63%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 27.5 26.5
Operating Profit Margin 26.99 24.91
Net Profit Margin 19.84 19.63
Q.5 Return on Asset of Mankind Pharma Ltd?
Mankind Pharma Ltd Return on Asset is 10.66%, which is below its 5 year historical median of 16.97%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Mankind Pharma Ltd?
Mankind Pharma Ltd Return on equity is 15.52% for FY-2025 , which is below its historical median of 20.3%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Mankind Pharma Ltd?
Mankind Pharma Ltd Return on capital employed is 17.05% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of Mankind Pharma Ltd?
Mankind Pharma Ltd Cash conversion cycle is 40 days, above its historical median of 19 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.55 0.93
ROE 15.52 20.3
ROCE 17.05 25.16
Cash Conversion Cycle 40 days 19 days
Q.9 Debt to Equity ratio of Mankind Pharma Ltd?
Mankind Pharma Ltd Debt-to-Equity ratio is 0.48 , which is above with the industry average of 0.13 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Mankind Pharma Ltd?
Mankind Pharma Ltd Debt to cash flow from operations is 3.04 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Mankind Pharma Ltd?
Promoters hold 72.66% of the Mankind Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Mankind Pharma Ltd vs industry peers?
Mankind Pharma Ltd revenue CAGR is 14.65% , compared to the industry median CAGR of 8.87% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 9,497.8 8,127.2
Gross Profit 2,612 1,337.7
Operating Profit 2,563 1,810
Net Profit 1,884 970
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.55 0.8
ROE 15.52 18.61
ROCE 17.05 17.96
Cash Conversion Cycle (days) 39.98 76

Valuation & price assessment

Q.1 Stock return of Mankind Pharma Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -17.79% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -17.8%
Q.3 Valuation ratios of Mankind Pharma Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 51 54.33 40.28
Price to Book 5.44 9.79 2.77
Price to Sales 8.77 37.52 2.65
EV to EBITDA 30.87 0.00 15.67

Check more companies

1. Lupin
2. Dr. Reddys Lab
3. Zydus Lifesciences
4. Mankind Pharma
5. Aurobindo Pharma
6. Alkem Laboratories
7. Glenmark Pharma
8. Laurus Labs
9. Biocon
10. Abbott India
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×